CARBIOTIX AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.082 SEK | -0.73% |
|
+30.99% | -79.50% |
| Apr. 25 | Carbiotix AB Signs First NutraCycle Joint Development Agreement with Leading Nordic Plant-Based Food & Beverage Producer | CI |
| Apr. 04 | Carbiotix Kicks Off Pilot Study for NutraCycle Service | MT |
| Sales 2022 | 3.11M 285K | Sales 2023 | 4.29M 392K | Capitalization | 8.29M 758K |
|---|---|---|---|---|---|
| Net income 2022 | -12M -1.1M | Net income 2023 | -13M -1.19M | EV / Sales 2022 | 16.1 x |
| Net cash position 2022 | 7.21M 659K | Net cash position 2023 | 2.66M 243K | EV / Sales 2023 | 1.31 x |
| P/E ratio 2022 |
-4.71
x | P/E ratio 2023 |
-0.62
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 86.91% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.73% | ||
| 1 week | +30.99% | ||
| Current month | -7.03% | ||
| 1 month | +0.99% | ||
| 3 months | -59.20% | ||
| 6 months | -88.61% | ||
| Current year | -79.50% |
1 week
0.05
0.09
1 month
0.050.09
Current year
0.050.97
1 year
0.052.00
3 years
0.0518.40
5 years
0.0528.95
10 years
0.0528.95
| Managers | Title | Age | Since |
|---|---|---|---|
Erik Deaner
CEO | Chief Executive Officer | 39 | 22-02-15 |
Henrik Ljung
DFI | Director of Finance/CFO | 66 | 20-03-31 |
Kristofer Cook
CHM | Chairman | 51 | 14-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kristofer Cook
CHM | Chairman | 51 | 14-08-31 |
Gustav Wendel
BRD | Director/Board Member | 42 | 19-07-31 |
| Director/Board Member | 44 | 22-02-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.082 | -0.73% | 2,879,432 |
| 24-04-25 | 0.0826 | +46.98% | 3,545,888 |
| 24-04-24 | 0.0562 | -4.10% | 1,291,808 |
| 24-04-23 | 0.0586 | -5.79% | 413,005 |
| 24-04-22 | 0.0622 | -0.64% | 638,798 |
End-of-day quote NORDIC GROWTH MARKET, April 25, 2024
More quotes
Carbiotix AB (publ) is a Sweden-based company with operations focused on intestinal health. The Company is engaged in microbiome healthcare through a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics, alongside a range of gut health testing services. The Companyâs business is conducted through four business legs: development of the prebiotic fiber Carbiotix AXOS, drug development linked to various metabolic and chronic diseases. sales of consumer and clinical tests for intestinal health and sales of medical food containing AXOS.
Calendar
2024-05-06
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -79.50% | 1.35M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CRBX Stock
